CHGC.F Stock Overview
Engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Chugai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥38.46 |
| 52 Week High | JP¥52.22 |
| 52 Week Low | JP¥29.75 |
| Beta | 0.50 |
| 11 Month Change | -9.80% |
| 3 Month Change | -16.75% |
| 1 Year Change | n/a |
| 33 Year Change | 6.13% |
| 5 Year Change | n/a |
| Change since IPO | 152.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHGC.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -19.7% | -1.4% | 0.3% |
| 1Y | n/a | 10.8% | 31.1% |
Return vs Industry: Insufficient data to determine how CHGC.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CHGC.F performed against the US Market.
Price Volatility
| CHGC.F volatility | |
|---|---|
| CHGC.F Average Weekly Movement | 14.4% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CHGC.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CHGC.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 7,604 | Osamu Okuda | www.chugai-pharm.co.jp |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Chugai Pharmaceutical Co., Ltd. Fundamentals Summary
| CHGC.F fundamental statistics | |
|---|---|
| Market cap | US$66.68b |
| Earnings (TTM) | US$2.50b |
| Revenue (TTM) | US$7.38b |
26.7x
P/E Ratio9.0x
P/S RatioIs CHGC.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHGC.F income statement (TTM) | |
|---|---|
| Revenue | JP¥1.14t |
| Cost of Revenue | JP¥337.17b |
| Gross Profit | JP¥805.18b |
| Other Expenses | JP¥418.22b |
| Earnings | JP¥386.96b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 235.16 |
| Gross Margin | 70.48% |
| Net Profit Margin | 33.87% |
| Debt/Equity Ratio | 0% |
How did CHGC.F perform over the long term?
See historical performance and comparison